ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

DARPA launches Nonsurgical Neural Interface project – Homeland Preparedness News

Continue reading

2018-03-20 Michael Zand NEWS

EAU 2018: Systemic Immunotherapy in Urological Cancers: Basics and Beyond – Monotherapy or Combinations for … – UroToday


Homeland Preparedness News

DARPA launches Nonsurgical Neural Interface project
Homeland Preparedness News
“DARPA created N3 to pursue a path to a safe, portable neural interface system capable of reading from and writing to multiple points in the brain at once,” Dr. Al Emondi, program manager in DARPA’s Biological Technologies Office (BTO), said. “High …

Continue reading

2018-03-20 Michael Zand NEWS

EAU 2018: Systemic Immunotherapy in Urological Cancers: Basics and Beyond – How to Evaluate the Benefit – UroToday

EAU 2018: Systemic Immunotherapy in Urological Cancers: Basics and Beyond – How to Evaluate the BenefitUroTodayCancer immunotherapy is an example of one of the newer strategies used to fight cancer, which primes or activates the immune system to produc… Continue reading

2018-03-20 Michael Zand NEWS

EAU 2018: Systemic Immunotherapy in Urological Cancers: Basics and Beyond – How to Evaluate the Benefit – UroToday

EAU 2018: Systemic Immunotherapy in Urological Cancers: Basics and Beyond – How to Evaluate the BenefitUroTodayCancer immunotherapy is an example of one of the newer strategies used to fight cancer, which primes or activates the immune system to produc… Continue reading

2018-03-20 Michael Zand NEWS

Process Discovered that Converts Blood Vessels to Blood Stem Cells During Early Development – Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology NewsProcess Discovered that Converts Blood Vessels to Blood Stem Cells During Early DevelopmentGenetic Engineering & Biotechnology NewsScientists from the Wellcome Sanger Institute in the UK and the European Molecula… Continue reading

2018-03-20 Michael Zand NEWS

Process Discovered that Converts Blood Vessels to Blood Stem Cells During Early Development – Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology NewsProcess Discovered that Converts Blood Vessels to Blood Stem Cells During Early DevelopmentGenetic Engineering & Biotechnology NewsScientists from the Wellcome Sanger Institute in the UK and the European Molecula… Continue reading

2018-03-20 Michael Zand NEWS

Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA Meeting – GlobeNewswire (press release)

GlobeNewswire (press release)Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA MeetingGlobeNewswire (press release)NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) — Incysus, Ltd., a biopharmaceutical company focused on delivering an inno… Continue reading

2018-03-20 Michael Zand NEWS

Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA Meeting – GlobeNewswire (press release)

GlobeNewswire (press release)Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA MeetingGlobeNewswire (press release)NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) — Incysus, Ltd., a biopharmaceutical company focused on delivering an inno… Continue reading

2018-03-20 Michael Zand NEWS
  • 1
  • …
  • 375
  • 376
  • 377
  • 378
  • 379
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

EAU 2018: Systemic Immunotherapy in Urological Cancers: Basics and Beyond – Monotherapy or Combinations for …
UroToday
The role of immunotherapy in bladder cancer continues to grow and currently is approved for the use in the second line setting and in the first line treatment in patient’s ineligible for platinum-based chemotherapy. As a second line agent immunotherapy …